Vantage Investment Partners LLC Increases Stock Holdings in Zoetis Inc. $ZTS

Vantage Investment Partners LLC grew its position in Zoetis Inc. (NYSE:ZTS) by 0.8% in the 2nd quarter, according to the company in its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm owned 77,103 shares of the company’s stock after buying an additional 593 shares during the period. Vantage Investment Partners LLC’s holdings in Zoetis were worth $12,024,000 as of its most recent SEC filing.

Other institutional investors and hedge funds also recently added to or reduced their stakes in the company. Lindbrook Capital LLC increased its position in shares of Zoetis by 1.8% during the 1st quarter. Lindbrook Capital LLC now owns 3,715 shares of the company’s stock worth $612,000 after purchasing an additional 65 shares during the last quarter. Scott & Selber Inc. boosted its stake in Zoetis by 0.6% during the second quarter. Scott & Selber Inc. now owns 11,652 shares of the company’s stock worth $1,817,000 after buying an additional 67 shares during the period. Secure Asset Management LLC increased its position in shares of Zoetis by 2.9% during the second quarter. Secure Asset Management LLC now owns 2,448 shares of the company’s stock valued at $382,000 after acquiring an additional 68 shares during the last quarter. Quotient Wealth Partners LLC raised its stake in shares of Zoetis by 2.3% in the 1st quarter. Quotient Wealth Partners LLC now owns 3,167 shares of the company’s stock valued at $521,000 after acquiring an additional 72 shares during the period. Finally, Broadway Wealth Solutions Inc. lifted its holdings in shares of Zoetis by 4.4% in the 1st quarter. Broadway Wealth Solutions Inc. now owns 1,746 shares of the company’s stock worth $287,000 after acquiring an additional 73 shares during the last quarter. Hedge funds and other institutional investors own 92.80% of the company’s stock.

Zoetis Stock Down 0.0%

Zoetis stock opened at $146.45 on Monday. The stock’s 50 day moving average price is $149.79 and its 200 day moving average price is $155.02. Zoetis Inc. has a 1-year low of $139.34 and a 1-year high of $196.55. The company has a market cap of $64.91 billion, a PE ratio of 25.21, a price-to-earnings-growth ratio of 2.35 and a beta of 0.90. The company has a debt-to-equity ratio of 1.05, a current ratio of 1.76 and a quick ratio of 1.04.

Zoetis (NYSE:ZTS) last released its earnings results on Tuesday, August 5th. The company reported $1.76 EPS for the quarter, beating analysts’ consensus estimates of $1.62 by $0.14. The company had revenue of $2.46 billion during the quarter, compared to the consensus estimate of $2.41 billion. Zoetis had a return on equity of 56.90% and a net margin of 27.83%.Zoetis’s quarterly revenue was up 4.2% compared to the same quarter last year. During the same quarter last year, the company earned $1.56 earnings per share. Zoetis has set its FY 2025 guidance at 6.300-6.400 EPS. On average, sell-side analysts predict that Zoetis Inc. will post 6.07 EPS for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have issued reports on ZTS shares. Leerink Partners lowered shares of Zoetis from an “outperform” rating to a “market perform” rating and cut their price target for the stock from $180.00 to $155.00 in a research note on Thursday, July 17th. Argus reaffirmed a “buy” rating and set a $190.00 price objective on shares of Zoetis in a research report on Tuesday, September 9th. Piper Sandler lifted their price objective on shares of Zoetis from $210.00 to $215.00 and gave the stock an “overweight” rating in a research report on Monday, August 11th. Weiss Ratings restated a “hold (c-)” rating on shares of Zoetis in a research note on Saturday, September 27th. Finally, Stifel Nicolaus downgraded Zoetis from a “buy” rating to a “hold” rating and dropped their price objective for the company from $165.00 to $160.00 in a report on Wednesday, June 18th. Five research analysts have rated the stock with a Buy rating and five have given a Hold rating to the company’s stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average price target of $200.88.

Zoetis Company Profile

Zoetis Inc engages in the discovery, development, manufacture, and commercialization of animal health medicines, vaccines, and diagnostic products and services in the United States and internationally. The company commercializes products primarily across species, including livestock, such as cattle, swine, poultry, fish, and sheep and others; and companion animals comprising dogs, cats, and horses.